Ultragenyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Ultragenyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Novato, CA, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the underwriters of the previously announced offering of 3,000,000 shares of common stock have exercised in full their option to purchase an additional 450,000 shares from the company at the public offering price of $54.00 per share, before underwriting discounts. The closing of the option exercise is expected to occur on February 19, 2015, subject to customary closing conditions.

Including the full exercise of the underwriters' option to purchase additional shares, the company's offering totaled 3,450,000 shares, representing gross proceeds of approximately $186.3 million and net proceeds of approximately $175.1 million after deducting underwriting discounts and other offering expenses.

Morgan Stanley, Cowen and Company, and Jefferies acted as joint book-running managers for the offering. Baird, Canaccord Genuity, JMP Securities, SunTrust Robinson Humphrey, and Wedbush PacGrow Life Sciences acted as co-managers for the offering.  

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became automatically effective on February 3, 2015. This offering is being made solely by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ultragenyx

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the expected closing of the public offering of the overallotment option exercise, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the terms to which the company has agreed or at all, uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Ultragenyx's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on February 3, 2015, as may be amended from time to time, together with its prospectus supplement filed with the Securities and Exchange Commission on February 5, 2015, and the documents incorporated by reference therein, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014, and its subsequent periodic reports filed with the Securities and Exchange Commission.

Contact Ultragenyx Pharmaceutical Inc.
For Media, Bee Nguyen
For Investors, Robert Anstey
- See more at: http://globenewswire.com/news-release/2015/02/17/706977/10120249/en/Ultragenyx-Announces-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html#sthash.jJjo3D1X.dpuf


Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.